Shots:
- The acquisition expands Novartis’ ophthalmology portfolio with the addition of Arctos’ pre-clinical optogenetics-based AAV gene therapy program and its technology
- The acquisition marks the Novartis commitment to identify optogenetics-based therapies for the treatment of patients with vision loss
- Arctos has developed its technology to treat IRDs and other diseases that involve photoreceptor loss, such as AMD. Arctos’ optogene is delivered to specific retinal cells using gene therapy to convert targeted cells into replacement photoreceptor-like cells
Click here to read full press release/ article | Ref: Novartis | Image: Reuters
The post Novartis to Acquire Arctos to Boost its Optogenetics Portfolio to Treat Eye Diseases first appeared on PharmaShots.
